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Introduction: Oral anticoagulant therapy choices for patients with atrial fibrillation (AF) 
expanded in the last decade with the introduction of direct oral anticoagulants (DOAC). 
However, the implementation of DOACs was slow and varied across different health 
economies in England. There is limited evidence on the patient role in the uptake of new 
medicines, including DOACs, apart from considering their demographic and clinical char-
acteristics. Hence, this study aimed to address the gap by exploring the view of patients with 
AF on factors affecting DOAC use.
Methods: A qualitative study using semi-structured interviews was conducted in three 
health economies in the North of England. Adult patients (>18 years) diagnosed with non- 
valvular AF, prescribed an oral anticoagulant (vitamin K antagonist or DOAC), and able to 
give written consent were recruited. Data were collected between August 2018 and April 
2019. Audio recorded interviews were transcribed verbatim and analyzed using the frame-
work method.
Results: Four themes with eleven subthemes discussed identified factors affecting the use of 
DOACs. They were linked to limited healthcare financial and workforce resources, patient 
involvement in decision-making, patient knowledge about DOACs, safety concerns about 
oral anticoagulants, and oral anticoagulant therapy impact on patients’ daily lives. Lack of a) 
opportunities to voice patient preferences and b) information on available therapy options 
resulted in some patients experiencing difficulties with the prescribed therapy. This was 
reported to cause negative impact on their daily lives, adherence, and overall satisfaction 
with the therapy.
Conclusion: Greater patient involvement in decision-making could prevent and resolve 
difficulties encountered by some patients and potentially improve outcomes plus increase the 
uptake of DOACs.
Keywords: uptake, new medicines, shared decision making, direct oral anticoagulants, 
DOACs, warfarin
Introduction
Atrial fibrillation (AF), the most frequently encountered cardiac arrhythmia, affects 
over 33 million people worldwide1,2 and accounts for approximately one-third of 
ischemic strokes.3 AF is associated with a five-fold increased risk of developing 
stroke,4 increased cardiovascular mortality and morbidity, and increased costs to 
health care systems.5,6 The risk of AF-related stroke can be reduced through antic-
oagulation therapy4,5 with oral anticoagulants (OAs), being the mainstream therapy 
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choice. The change of AF-related stroke risk calculation 
from CHADS2 to CHA2DS2-VASc score and removal of 
the recommendation for antiplatelet therapy in national 
and international guidelines4,7,8 further encouraged the 
use of OAs.5
OA therapy choices for patients with non-valvular AF 
have expanded in the last decade. Vitamin K antagonists, 
predominantly warfarin, were the OAs of choice before the 
introduction of four direct oral anticoagulants (DOACs).6,9 
DOACs have been shown to be as effective as warfarin in 
preventing AF-related stroke.9 DOAC therapies reduce the 
need for regular coagulation monitoring, have simpler dosing 
regimens, and fewer known drug or food interactions4,6,9 and 
have therefore led to a decrease of warfarin and increase of 
DOAC use in patients with AF.10
Despite these clinical benefits, the overall uptake of 
DOACs in England has been relatively low and slow.11 
The average uptake was only 16.5% in 2015 with a high 
level of unexplained variation across different health 
economies in England, ranging from 4% to 70% of all 
OA prescribing.11 Reported barriers for DOAC use 
included affordability by patients or health systems,12–17 
prescriber’s lack of experience or knowledge of anticoa-
gulation, DOAC use or both,12,14–16,18–20 and safety 
concerns.9,14,21,22 Other factors that are reported to influ-
ence OA prescribing decisions include patient clinical 
characteristics,12–15,19,23 peer prescribing practice,22 
national guidelines and scientific literature,22 perceived 
benefits over existing warfarin therapy,14,22 and practice 
characteristics.16,20,22,24
However, there is a shortage of evidence on the 
patient’s role on the uptake of new medicines, including 
DOACs, apart from considering their demographic and 
clinical characteristics.25 Since patient involvement in 
medicine-related decision making is an important indicator 
of good quality healthcare,4,26,27 prescribing decisions, 
such as initiating warfarin or a DOAC should be shaped 
by patient preferences. Involvement of patients with AF in 
the decision-making about oral anticoagulation therapy has 
been reported to be minimal to none.28,29 The evidence 
shows that decisions in consultations were often domi-
nated by prescribers, with patients having limited oppor-
tunities to express their preferences or choose between 
different therapy options.28,29 Often patients were not pro-
vided with complete information, the selection of informa-
tion being influenced by prescribers’ views and local 
protocols, to steer them towards the prescribers’ or orga-
nizations’ preferred option.28,29 For example, Choi et al30 
found that patients initiated on warfarin were less likely to 
be told about DOACs in consultations, thus limiting 
their use.
Further evidence is needed on patients’ views and 
experiences to gain a better understanding of the opportu-
nities and barriers for DOAC use. Identifying these factors 
could help to deliver more patient-centred care to patients 
with AF and improve uptake of new medicines like 
DOACs. This study aimed to explore patient perspectives 




A qualitative study was conducted using face-to-face, 
semi-structured interviews. Interviews were undertaken 
between August 2018 and April 2019 using a developed 
interview guide, informed by findings of a narrative 
review conducted by the research team.29 The guide con-
sisted of eight open-ended questions with associated 
probes and prompts exploring patients’ experiences of 
consultation and involvement in decision-making when 
an OA was started, knowledge of available OAs, and 
views on the availability of new medicines, including 
DOACs, in the NHS (see Supplementary file 1). Ethics 
approval was granted by South Central-Oxford B Research 
Ethics Committee (18/SC/0284). The study was conducted 
in accordance with the Declaration of Helsinki.
Patient and Public Involvement (PPI)
Three people with AF taking oral anticoagulation for 
stroke prevention formed a PPI advisory group. Details 
of their involvement have been described in-depth 
elsewhere.31
Setting and Participant Recruitment
Patients were recruited from three health economies in the 
North of England. These health economies were selected 
due to different levels of DOAC uptake and having differ-
ent mechanisms for approval and support of entry of new 
medicines into practice (see Supplementary file 2 for 
description of each health economy).
Theoretical sampling32,33 was employed to recruit eligi-
ble participants. A sample size of eight participants from 
each health economy (total 24) was deemed sufficient to 
achieve data saturation based on previous research.21,34,35 
The recruitment of participants stopped once data saturation 
https://doi.org/10.2147/PPA.S302016                                                                                                                                                                                                                                  
DovePress                                                                                                                                               
Patient Preference and Adherence 2021:15 954
Medlinskiene et al                                                                                                                                                   Dovepress

































































was reached (ie, the point when new interviews provided 
little or no change to the thematic development).36 Eligible 
participants were adult patients (>18 years) diagnosed with 
non-valvular AF; prescribed an OA (vitamin K antagonist 
(eg, warfarin) or DOAC) therapy; able to give informed 
consent; understand written and spoken English or have a 
family member willing to interpret. Patients who were 
deemed to be inappropriate to include in the study by their 
direct care team (eg, end-of-life care patients, patients with 
dementia) were excluded.
Potential participants were identified and approached 
by a member of their direct care team (nurse or pharma-
cist) in secondary and primary care anticoagulation or 
arrhythmia clinics. The PPI advisory group members 
recruited patients from a local patient support group. Up- 
to 30 patients were approached in each health economy 
and received an invitation letter and a study information 
leaflet with a consent form. Interested patients contacted 
the researcher (KM) for further information and were 
further assessed for eligibility. Informed written consent 
was obtained from all recruited participants and included 
publication of anonymized responses. Participants were 
offered reimbursement for their travel expenses if 
required, and a £10 high-street voucher as a token of 
appreciation for taking part.
Data Collection
The researcher (KM) conducted interviews at a time and 
place convenient to participants. Interviews were audio- 
recorded and transcribed verbatim.
Data Analysis
Inductive thematic analysis using the framework method37 
was employed. It involves the creation of an analytical 
framework used to organize the data into a matrix. The 
method provides a clear audit trail to the analysis process 
as the development of themes can be linked back to the 
original data. Thus, potential researcher bias is 
minimised,37–39 increasing rigour and trustworthiness in 
the data analysis.37,40
An analytical framework was developed by inductive 
coding of five interview transcripts (KM, SR) and refined 
after application to another five transcripts and discussions 
by the research team (KM, SR, DP). The analytical frame-
work facilitated the organization of the data and creation 
of five matrices, recorded using NVivo (version 11). Each 
transcript was re-read to summarize the data in each cate-
gory of the matrix. Then, each matrix was individually 
cross-examined to identify key elements within each 
matrix, patterns, and connections across cases, and when 
data saturation occurred. Grouping of the identified ele-
ments led to the development of potential themes and sub- 




A total of 21 patients were interviewed in the study 
(Table 1). The age of participants ranged from 55 to 83 
years, mean 72 years. Of 21 participants, ten patients were 
taking warfarin, the remainder were taking a DOAC: six 
rivaroxaban, three apixaban, one dabigatran, and one 
edoxaban at the time of the interview. Two patients taking 
a DOAC had previously taken warfarin, and one patient 
experienced a switch between two different DOACs. The 
median (IQR) time of taking a prescribed OA was 3 years 
(4 weeks-7 years), warfarin 7 years (3–9 years) and DOAC 
1 year (4 weeks-4 years)
Framework Analysis
Four themes with eleven sub-themes were developed 
(Figure 1). The themes were: limitations of NHS resources, 
clinician-patient encounter, OA knowledge, and impact of 
therapy on daily life. Supportive verbatim quotes from parti-
cipants for each theme are presented in Table 2.
Theme 1: Limitations of NHS Resources
This theme presents patients’ views about NHS resources, 
specifically limitations of these resources, and how it 
affected the choice of OA therapy they were offered. The 
theme is presented in three subthemes: medicine cost con-
siderations, consultation time constraints, and varying 
local services.
Medicine Cost Considerations
Many interviewed patients were acutely aware that the 
NHS has a limited financial budget and needed to conti-
nually try to save money. Hence, many patients accepted 
the preference to use less expensive medicines as a stan-
dard practice within the NHS. Most patients perceived 
DOACs to be more costly than warfarin and expected 
warfarin to be favored over DOACs. However, some 
patients started on warfarin questioned if warfarin therapy 
was indeed a cheaper option due to the associated mon-
itoring requirements, especially in the long term. Some 
even suggested that the use of DOACs would help the 
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NHS to save money by releasing staff from warfarin 
monitoring clinics to see other patients. Nevertheless, not 
all patients were happy that cost may be prioritized in 
therapy decisions. Some patients wished therapy options 
were tailored to their needs by considering their health 
status, lifestyle, and preferences. Some said they would 
be willing to pay for the new, more expensive medicine if 
it meant a better quality of life.
Consultation Time Constraints
Many patients, when starting anticoagulation, stated the 
standard ten minutes allocated to a consultation with a GP 
was not enough to discuss therapy options. Some patients 
thought that asking for an explanation about medicines 
was wasting doctors’ time. They feared becoming a burden 
to the system that was perceived to be already under 
pressure. Some patients suggested that longer consulta-
tions were needed to involve patients in the decision- 
making process. However, others were clear that having 
an extended consultation was not possible due to the NHS 
being short of the qualified personnel and overwhelmed 
with patients. Despite consultation constraints, some 
patients discussed work-around strategies. For instance, 
some patients booked two instead of one appointment 
with their GP. Some patients also experienced a variation 
of consultations between different GPs with some GPs, 
giving the time the patient needed, whereas others were 
stricter with the time. Some also indicated that consulta-
tions at the hospital outpatient clinics, eg, warfarin, offered 
more time to have an in-depth discussion than possible 
with GPs. Furthermore, patients taking warfarin did not 
expect to be informed about alternative therapy options. In 
their opinion, both patients and doctors, because of limited 
time in consultations, prioritized resolving the presenting 
issues rather than improving what was perceived as 
already working.
Varying Local Services
A few patients wondered if, in the area they live, only 
certain medicines were available. For instance, one patient 
recalled their previous experience with the NHS of avail-
ability of service depending on their geographical location. 
They thought that might apply to the availability of new 
medicines, including DOACs, as well. Some patients ques-
tioned if established local services could dictate what 
medicines were offered to patients. For instance, one 





Sex Age OAC Taken Duration of 
Taking OAC
Reported Side Effects
P1-A-D A Male 58 rivaroxaban 2 years None
P2-A-W A Male 83 warfarin 15 years Bleeding
P3-A-W A Male 65 warfarin 6 years None
P4-A-W A Male 70 warfarin 8 years Bruising
P5-A-W A Male 81 warfarin 23 years None
P6-A-D A Female 82 rivaroxaban 4 years None
P7-A-W A Male 76 warfarin 10 years None
P8-A-W A Male 78 warfarin 3 years None
P9-B-W B Male 64 warfarin 3 years None
P10-B-W B Female 55 warfarin 2 years Nose bleeds
P11-B-W B Male 73 warfarin 2 weeks Eye bleed
P12-B-W B Female 69 warfarin 9 years None
P13-B-D B Male 73 edoxaban 3 weeks None
P14-C-D C Female 79 apixaban 2 years None
P15-C-D C Male 72 rivaroxaban 4 weeks None
P16-C-D C Male 65 apixaban (previously rivaroxaban, warfarin) 4 weeks Cold feeling and bruising with all
P17-C-D C Male 65 rivaroxaban (previously warfarin) 1 year Fatigue with warfarin
P18-C-D C Female 75 dabigatran 5 years Fatigue
P19-C-D C Male 80 rivaroxaban 5 years None
P20-C-D C Male 78 rivaroxaban 10 weeks None
P21-C-D C Male 77 apixaban 8 weeks None
Notes: *Participant name included patient number (eg, P1), health economy the patient was from (A, B, or C), and oral anticoagulant taken (W: warfarin or direct oral 
anticoagulant). 
Abbreviation: OAC, oral anticoagulant.
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patient speculated that only warfarin was offered to them 
because there was an established warfarin clinic at their 
GP practice. Another patient was given an impression by 
their GP that the warfarin clinic at a hospital rather than 
the GP or the patient made the decision which OA to 
prescribe.
Theme 2: Clinician-Patient Encounter
This theme describes patients’ experiences and views on 
their interactions with the clinician and how it affected 
their involvement in the decision-making about therapy 
choices. It is presented in three subthemes: perceived 
roles, relationship continuity, and prescribing habits.
Perceived Roles
Some patients reflected they were brought up to accept 
doctors’ authority. It was the clinician’s role to make 
decisions and the patient’s to tell their symptoms and 
follow the clinician’s instructions. A few patients com-
mented that being involved in the decision-making process 
had never occurred to them and said that questioning the 
clinician indicated a lack of respect. Also, some patients 
viewed that there was only a choice between accepting or 
refusing anticoagulation. Hence, some patients thought 
there was no need for their involvement, especially when 
only one therapy option was presented, as they would 
choose anticoagulation to prevent stroke. Some patients 
recalled being diagnosed with AF and started on an OA 
during an acute hospital admission. They described at the 
time feeling unwell and worried about their health and 
having a stroke. Hence, in these circumstances, patients 
did not feel it was the right time for them to get involved 
in the decision-making about the choice of OA therapy, 
and they detached themselves from participation. Most 
patients believed and expected that doctors would make 
the best and right decision tailored to their needs and 
circumstances. Some of these patients started on warfarin 
or a DOAC, had high trust in clinicians and were satisfied 
with little or no involvement in decision-making. In con-
trast, other patients wished they had an opportunity to 
discuss the therapy options, why they needed it, and its 
implications in more detail. This was particularly the case 
for patients who were unsatisfied with their current OA 
therapy, mostly warfarin. They reasoned that they should 
have a say in the choice of the therapy as they are going to 
have to live with the decision made. Some patients started 
on a DOAC experienced making the decision together 
with the doctor as they were offered more than one therapy 
option and an opportunity to voice their preferences. Two 
patients described making the decision themselves.
Relationship Continuity
Some patients described experiencing a lack of relationship 
continuity with their clinicians as they saw a different clin-
ician every time, they had an appointment at GP practice. 
They felt that a new doctor did not know their medical 
history, which prevented being involved in the decision- 
making process, or having enough support when choosing 
between OA options. When asked, patients indicated that 
they prefer to see a regular doctor who knows them. Hence, 
they could develop a relationship with the clinician, ask 
questions, and consequently get involved in the discussion 
Figure 1 Summary of Developed Themes and Sub-Themes from the Interview Data with Patients.
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Table 2 Quotes Supporting Themes and Sub-Themes
Theme Subtheme Quotes




“He [GP] was clearly saying we always start with warfarin because it is affordable, the other 
medication they are costly … This is [warfarin] costing NHS plenty of money because when I go to 
the clinic, I am using the time of the secretary, the time of the nurse, the material for checking, the 
device, the paper, the time of the nurse or the pharmacist, all that is recovered from the time of … 
for the cost of this. For me, I just thinking about, okay, I am having every three weeks going to speak 
with nice people, checking my condition - that’s fair enough but is this looking right by the NHS? No, 
I do not think [the] NHS [is] helping themselves prescribing this medication [warfarin] while if they 
prescribe these medications [DOACs] will require only to take it once and forget about it, they will 
save more than the money they save from prescribing [warfarin].” (P9-B-W)
“I mean they [NHS] are very sensitive to cost, aren’t they? If you can save a bob, save it, I understand 
that because they are always strapped for cash.” (P11-B-W)
“I think the key point is there may be something better for me and I want to have that discussion and 
if somebody said to me, ‘Well you know we can’t afford it on the NHS’, well fine I will pay for it 
privately. I do not mind, if that gives me something a lesser risk, a better lifestyle because to me it’s 
not the longevity it’s more about quality.” (P3-A-W)
Consultation time 
constraints
“Well if the doctor was going to sit and offer me options and discuss the pros and cons of the 
various medicines which might be available, then a 10-minute appointment isn’t going to cut the 
mustard is it?” (P18-C-D)
“You know the health service is under a great deal of stress at the moment, I am okay I have not 
died yet, I do not have anything that’s affecting my lifestyle that I need to go back seeing the doctors. 
Therefore, I do not go back, I am not going to knock on his door and say I want this or I want that, I 
want that or whatever else. So, no I do not feel empowered to do that but I’d like to be.” (P3-A-W)
“ … if you went to inform the people on warfarin about a new one where would you get your 
millions from, it would be a very expensive procedure … If you were offering them a choice of three 
you would need to give them the information again cost … I mean if you have gone with something I 
do not know pain within your stomach, you are not going to be bothered about talking about the 
possible improvement you get from something else if it was going to detract from why you had gone 
… ” (P5-A-W)
“They say its 10 minutes per patient. I mean I can go up to the doctors …. I can be waiting an hour 
before I even go in. I think as timewise, as I say, all doctors are different. Some doctors like the 
doctors up there [his GP practice], a couple of them up there, I will go in there and I will sit, and 
they will talk and talk until I am ready to go. You have got another doctor will be in there and is 
precise. In blah, blah ….and you are out. You are out in your 10 minutes.” (P20-C-D)
Varying local 
services
“Also you get the feeling why was not I offered the new stuff ….was it because there is a very well 
established warfarin clinic at the practice every Friday and it’s easy just to work with one drug rather 
than four, I do not know … and more you know we have done this, this is how we do things here, 
it’s warfarin and warfarin only right now … ” (P3-A-W)
“ …. it’s not up to you, it is up to clinic, if the clinic they see that warfarin doesn’t work for you then 
they will go and give you, they advise you to all different medication.” (P9-B-W)
“ … my daughter had cancer. Now when we applied for a wig, because of our postal code, she was 
not allowed that on the National Health. But if I had gone over to the other side of town, she was 
allowed the wig. And that is exactly the same with medicines is not it? And some of it, whether that’s 
true or what I do not know on costing and your postal codes again, if it is depending on which postal 
code you have got you get a dearer medicine because there are cheaper medicines and dearer 
medicines is not there?” (P13-B-D)
(Continued)
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about available therapy options. However, most patients 
stated that trying to see the same doctor was challenging. 
Only a few patients described seeing a regular doctor and 
experiencing good communication with them. Some patients 
started on warfarin described building a relationship with the 
pharmacists at the warfarin clinic and being able to ask them 
questions and therefore becoming more involved in their 
management of warfarin. A few patients described using a 
community pharmacy for additional advice or information as 
they had built a relationship with them.
Prescribing Habits
Despite many patients seeing doctors as experts, some patients 
queried prescriber knowledge and experience that could 
potentially affect the use of new medicines. Some patients 
suggested that doctors might not be aware of the latest infor-
mation about available DOACs. Hence, patients would not be 
informed about DOACs during their consultation, and the 
doctor would not prescribe them. Some patients suggested 
that some doctors were unwilling to change their prescribing 
habits due to their familiarity with warfarin and the established 




Perceived roles “I think it’s the history of how the NHS works, I think they are being very much a doctor this, 
doctor that, doctor says you should do so and so, oh right so you do it. Doctor says chop my hand 
off, okay, you know. People are not used to asking doctors questions or question that doctors might 
not be right. Nor am I.” (P11-B-W)
“It was that [warfarin] or nothing, on or off. I could have said yes and no, well yes or no did I want it 
or not, but it would be crazy not to go onto it. “(P3-A-W)
“I like to be told you know these are the options, these are the pros, these are the cons … I like to 
be part of the decisions, I would prefer … where it’s almost a joint decision” (P3-A-W)
“We have both got a say, that’s it discussed, you know, the pros and the cons for it and then you can 
put your point of view forward and the consultant put his and hopefully you’ll come to some mutual 
agreement ….I think it’s much more beneficial for both the consultant and myself to have a 
discussion about it and both decide which one might be best.” (P14-C-D)
“I was not well. I was too poorly. I was happy to be in there [hospital] receiving wonderful attention 
and I was getting some medication of what I needed … I know that anything blood going through the 




“I mean you go in and I see names come up, and I haven’t a clue who they all are, it’s different 
doctors then next news they’ve gone, and there’s somebody else up there.” (P6-A-D)
“If you get someone that you see on a regular basis, at the other place there was someone that is 
possibly your GP if he’s not available, you see someone else, yes, when you see the same one he 
knows what you are doing, he knows your story a bit more than the other one, the other one is 
spending 10 minutes trying to read your information on the screen. So, the consultation is going to 
be 10 minutes, so at the end of the story, he just says, ‘Here, have this,’ and he goes. Yes, obviously, it 
makes a difference.” (P17-C-D)
“I do speak to my pharmacist because I’m very friendly with him. It’s actually in the doctor’s surgery, 
and he is a nice man I spoke to him about things, and he’s always advised me.” (P20-C-D)
Prescribing habits “It’s probably the doctors not being up to date with what usage they [DOACs] are … ” (P8-A-W)
“ … there is certainly from my experience this comfort with warfarin, it has been used, it has been 
tried, we have got dozens of patients on it, we have a system set up to monitor it … ” (P3-A-W)
“ … because some places the doctors they are flipping old …. I don’t think some of them want to 
pick up about new … read about new pills … some of them are stuck in the past” (P1-A-D)
(Continued)
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warfarin prescribing and monitoring service. Hence, patients 
viewed doctors being more comfortable with prescribing war-
farin. Others believed doctors had a preferred OA as it was 
easier to learn and work with one rather than be familiar with 
five different OAs.
Theme 3: Oral Anticoagulants Knowledge
This theme considers patients’ knowledge about OA ther-
apy options and how it influenced their preferences. It is 
presented in three subthemes: awareness of therapy 
options, safety concerns, and efficacy.






“I knew about warfarin before because I knew from acquaintances who were on warfarin and what it 
involved.” (P18-C-D)
“I have had no discussion about any of them at all. “ (P10-B-W)
“As I say just literally searching online and looking at you know what was recommended for blood 
thinning … you think do I really want to be taking that sort of stuff [warfarin], isn’t there anything 
better really, hasn’t science brought anything else.” (P3-A-W)
“When I left the hospital, I have my younger brother who is a consultant orthopaedic, he was 
thinking well they might prescribe warfarin or some other medication where you do not need any 
testing. So I was waiting for the hospital to send me an appointment. Then I went to hospital, 
straight away they asked me to go to warfarin clinic ….I did not challenge it and when I had the 
problem to get it right [INR], when I asked my GP [about the alternative to warfarin].” (P9-B-W)
“Warfarin is doing that for me so why would I change it? I’m inclined to say that if it’s not broken 
don’t try to mend it and as far as I’m aware warfarin’s working, so I’d leave it alone.” (P4-A-W)
Safety concerns “If there was an alternative medication which has less potentially bad side effects, I would obviously 
go for it.” (P11-B-W)
“[I] knew people that had had it [warfarin] at some time or another, so I opted for that as perhaps 
the safer option … warfarin has been around a long time; it must be reliable. The other one, I have 
never heard of it, do not know how long it has been around, got to be suspect.” (P8-A-W)
“There were one or two people at the gym that have got exactly the same thing … They have had 
one or two side effects with the warfarin … with heavy bleeding and stuff like that. And I thought 
well I do not want that really.” (P18-C-D)
“ … the doctor would say ‘this is a new medicine; try it and we will see how it goes’. I mean things 
like that are not irreversible are they, you can stop using them straight away if they are not having 
the effect or having an adverse effect.” (P4-A-W)
“So that [monitoring] is what swayed me to keep taking warfarin, because I mean it is quite a serious 
thing to be taking is not it, you know, a blood thinner …. I think it is a bit dodgy if they are going to 
give you a tablet, though, and never call you back … I do not know when they see you again, if at all. 
Nobody seems to know. How do they know the dosage is right? I would probably feel safer with the 
warfarin knowing I can go and let them check it.” (P7-A-W)
Efficacy “If there’s been plenty of people actually got benefit from it and I could be furnished with the volume 
of information showing that it is beneficial for old goats like me, then I would say “Yeah give it I have 
a try at that” ‘cause it’s me that’s going to have the stroke if these things do not work and strokes we 
do not want.” (P8-A-W)
“I just said to him [pharmacist] ‘what’s with this rivaroxaban they’ve put me on. Is it good?’ and he 
told me. He said, ‘no, it’s very good. It’s a new one compared to the warfarin,’ he said … I was happy 
enough to take it.” (P20-C-D)
(Continued)
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Awareness of Therapy Options
Before the initial consultation, some patients were already 
familiar with warfarin. They learned about it from their 
social networks (eg, family, friends) and/or professional 
networks (eg, working in healthcare). Some of these 
patients were involved in the decision-making about the 
choice of OA and used prior knowledge to inform their 
decisions and preferences. Few patients knew about 
DOACs before their consultations. During a consultation, 
many patients on warfarin and some on DOAC therapy 
said they were not given a choice and told only about one 
OA. Patients also discussed their lack of knowledge about 
therapy options, the condition, and what was happening 
with them, preventing them from being involved in the 
decision-making. These patients relied on the doctor’s 
expertise and did not question the therapy choice made. 
However, patients who were experiencing issues with 
warfarin sought information about alternatives to warfarin 
from family or friends with medical education or taking an 
OA, print media and the Internet. Newly acquired 
knowledge about DOACs motivated some to ask their 
clinicians about switching from warfarin to DOAC ther-
apy. Some patients who were satisfied with their pre-
scribed therapy were not interested in learning about 
alternative therapy options.
Safety Concerns
Patients accepted that all medicines have side effects but 
would prefer a treatment with less severe or more manage-
able ones. Most patients sought information about a med-
icine’s side effects profile, and some compared the side 
effects of warfarin and DOACs when making therapy 
choices. Several patients also voiced concerns about the 
unknown side and long-term effects of DOACs as they 
were new medicines. In contrast, warfarin was perceived 
to be a well-tested medicine with established side-effects 
and long-term effects and thus a safer option than a 
DOAC. Others viewed a DOAC as a safer option due to 
themselves or people in their social network having 
experienced side effects with warfarin, eg, bleeding. 
Table 2 (Continued). 
Theme Subtheme Quotes
Impact on daily life Lifestyle changes “We are very conscious of our diets here.” (P8-A-W)
“We will fit the warfarin around you rather than the other way around and I think that made a 
significant difference to how you approach taking it and it’s not going to rule your life and you can 
live a normal life without worrying about having to be tested all the time.” (P10-B-W)
“Every time before I go on holiday I inform them so we will … try to do a test just before my holiday 
and test after the holiday … so always they make sure that my holidays are very limited but when I 
go abroad … when I fast, I tell them this is fasting month and my diet will be completely different, I 
will be not eating and drinking for 18 hours, 17 hours, so they are aware of that and they try to 
make appointment as a prior or after that change of my circumstances.” (P9-B-W)
“I just take one a day, and I do not bother. I think even they do not bother me”. (P6-A-D).
Monitoring and 
dosing changes
“If my work changes and I need to have like leave to go to hospital I would say no, this is not working 
for me, but at the moment with my circumstances, I can control my time, I have no problem.” (P9-B- 
W)
“The only downside is that I don’t know if you know the area, but where the doctor’s surgery is, it’s 
at the top of a massive hill, and I have to walk up there because I have no transport, and there is no 
bus.” (P2-A-W)
“Although I was retired, and I was about 70, I was still working and traveling, and it [DOAC] suited 
my lifestyle … had he put me on warfarin, I would have had to go every month for check-ups, and 
that would have seriously interfered with my lifestyle.” (P18-C-D)
“I was taking warfarin, and I was to go in every month to have the blood test and then have a 
different dose. There were like millions of bloody tablets because I used to take like three single 
ones, two of these, one of that, just I could not even remember them.” (P17-C-D)
Abbreviations: GP, general practitioner; DOAC, direct oral anticoagulant; NHS, national health service.
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Some patients also questioned the safety of warfarin due to 
its negative connotation of being developed initially as a 
rat poison. Other patients admitted not knowing the side 
effects of OAs nor reading patient information leaflets 
because the prescribed medicines were assumed to be 
safe. Also, some patients suggested if they experienced a 
side effect, they could stop and change it to an alternative 
OA. Many patients were aware of or experienced regular 
monitoring with warfarin, which gave them the feeling of 
safety, comfort, and being looked after. Hence, they had 
expected the same level of monitoring with DOAC ther-
apy. Patients had concerns and a lack of understanding 
about infrequent or no monitoring associated with DOAC 
therapy. These concerns were further amplified by 
patients’ perception that doctors had a lack of understand-
ing about it. Consequently, these patients felt warfarin with 
associated regular monitoring was a safer option.
Efficacy
Some patients talked about the effectiveness of OAs. 
Patients agreed that taking an OA would prevent AF- 
related stroke. They wanted to be informed about new 
medicines as they might be better and more reliable than 
their currently prescribed OA therapy. Many patients did 
not question the effectiveness of either DOAC or warfarin 
therapies. However, one patient said they would need 
more information about a new medicine for assurance 
that it would be effective in their age group before con-
sidering taking it, whereas another patient thought a new 
medicine would have more research evidence to show its 
effectiveness compared to older medicines and therefore 
was happy to take it. Also, some patients taking DOAC 
therapy looked for assurance that the prescribed medicine 
was effective by searching for information on the Internet 
or consulting with their community pharmacist.
Theme 4: Impact on Daily Life
This theme describes the impact of taking OAs on 
patients’ daily lives and how it affected their preferences 
for an OA. It is presented in two subthemes: lifestyle 
changes and monitoring and dosing changes.
Lifestyle Changes
Patients on warfarin reported adjusting their lifestyle to fit 
with the medicine prescribed. Patients taking warfarin 
were aware of certain foods interacting with warfarin and 
thus adjusted their diets, eg, reducing intake of vitamin K 
rich foods or alcohol. The impact of the adjustments 
required varied between patients. For some patients, it 
caused no difficulties, and they were happy to continue 
with warfarin. Some were also told by their clinicians that 
warfarin will be adapted according to their diet instead of 
patients needing to change their diets. Consequently, the 
explanation allowed them to continue with their desired 
diet and made the idea of taking warfarin more feasible 
and less disruptive to their lifestyle. Other patients 
described that warfarin caused issues due to their changing 
diets and travelling abroad. One patient described how, 
together with the clinicians, they agreed warfarin monitor-
ing and dosing to manage changes of circumstances such 
as taking a course of antibiotics, fasting, or when going on 
holiday. A few patients described adjusting their holiday 
plans because of warfarin, eg, shorter duration, no travel 
abroad. Other patients stated that they declined warfarin 
and chose DOAC as they travelled frequently abroad. 
Patients taking DOACs described minimal to no impact 
on their lifestyle.
Monitoring and Dosing Changes
Patients described the impact of required monitoring and 
resulting dosing changes. As with impact on lifestyle, 
patients taking DOACs described minimal to no impact. 
The impact of the adjustments to daily lives varied 
between patients taking warfarin. Some patients had no 
issues in attending warfarin clinics but acknowledged that 
their situation might change in the future, for example a 
change in job or health status, and they would need to 
reconsider their OAs options. Some patients who were 
started on warfarin without having a different option pre-
sented thought doctors did not consider their circum-
stances when making prescribing decisions. These 
patients had challenges getting to the warfarin clinic due 
to lack of their own transport, reduced mobility, or unable 
to take time off work and therefore missed some of their 
appointments. Hence, some patients declined warfarin due 
to perceived challenges associated with regular monitor-
ing. Also, some patients described occasionally forgetting 
to take the correct dose or missing a dose of warfarin, 
particularly as the dosing regimen frequently changed. The 
challenges with warfarin therapy encouraged some 
patients to enquire about alternative options. However, 
some of these patients were told they could not have 
DOAC therapy. Hence, they discussed strategies to lessen 
the impact of warfarin on their daily routines. Some asked 
for monitoring to be done closer to their home, eg, at a 
local GP practice. Others explored self-monitoring at 
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home option but were told it was not available. Some 
described strategies to remember to take warfarin and 
correct dose, eg, using telephone application to record 
warfarin doses and set reminders when to take the dose.
Discussion
This study provides a novel contribution to the literature 
on DOAC uptake by exploring patients’ views on the 
factors influencing DOAC use for stroke prevention in 
AF. The findings from this study provide important 
insights that could enable care providers to improve AF 
stroke prevention care. While there were a wide range of 
experiences and views, altogether patient narratives reveal 
a number of important factors for clinicians and others 
involved in patient care to consider. Altogether these fac-
tors influenced what OA therapy options were presented 
and prescribed to patients and consequently influenced 
patients’ satisfaction with the prescribed therapy.
Our study findings indicate that barriers to DOAC use 
were often linked to lack of patient involvement in deci-
sion-making, which can result in patients not being aware 
about DOACs as a therapeutic option. Most patients on 
warfarin reported no or limited involvement in decision- 
making, which agreed with previous work.28,29 These 
patients were not informed about DOACs and had no 
opportunity to influence the choice of therapy prescribed. 
As some patients prescribed warfarin would have pre-
ferred DOAC therapy, lack of involvement in decision- 
making was a barrier for DOAC use.
Patient narratives identified that main barriers for 
patient involvement included some patients viewing it 
was the clinician’s role to make decisions or did not 
think they could be involved due to historical ways of 
consulting; patient’s lack of knowledge about AF or OAs 
and thus confidence in making-decisions; not seeing a 
regular clinician and lack of relationship; acute hospital 
admission; and limited time in consultations. These factors 
were consistent with previous studies identifying barriers 
for patients with AF involvement in decision-making 
around anticoagulation therapy.28,29 Lack of therapy 
options presented resulted in some patients having nega-
tive experiences with warfarin as it did not align with their 
lifestyle and thus, they experienced challenges with attend-
ing required monitoring and taking correct doses. 
Clinicians are in a position to engage and empower 
patients to become more involved in the decision-making 
by providing information on available therapy options, 
establishing their needs and preferences, and accepting 
patients’ decision, which may or may not differ from the 
prescribers’ preferred choice.
Several barriers to DOACs use were linked to charac-
teristics of consultations. Firstly, limited consultation time, 
especially in primary care, was highlighted as a barrier. 
Our findings indicated that there was not enough time to 
discuss different OA options. Thus, patients were 
informed about an OA preferred by the prescriber. 
Consequently, prescribing decisions were seen to be influ-
enced by prescriber preferences, which could be a barrier 
to DOAC use if warfarin was favoured.41 Some suggested 
that longer consultations were needed but noted it would 
not be feasible due to a shortage of clinicians in the 
healthcare service. Required additional time was also 
noted to add extra spending in already perceived cost- 
conscious healthcare system. Secondly, the timing of the 
initial consultation was important. Some patients discussed 
that in situations when they were unwell and concerned 
with surviving or getting better, eg, acute hospital admis-
sion, they were not able to take in the information and be 
part of the decision. Thus, the prescribed therapy was 
based on prescribers’ preference. Thirdly, some patients 
argued that patients already established on warfarin would 
not be informed about DOACs due to additional clini-
cians’ time required and the high cost of DOACs. 
Patients should be provided with routine reviews to be 
involved in reviewing prescribed therapy once their health 
has improved or alternative therapy, eg, DOACs, became 
available. The review could be performed in anticoagula-
tion clinics led by pharmacists, which are reported to have 
high patient satisfaction.42,43
Participants also showed knowledge about the higher 
cost of DOACs compared to warfarin, which was high-
lighted as potential barrier to their use in the “cash- 
strapped NHS”. Although DOACs were deemed as cost- 
effective medicines by national guidance in England and 
some patients viewed them as more cost-effective than 
warfarin in the long term, some patients were of opinion 
that warfarin was favored by prescribers due to cost. They 
believed it was one of the reasons why they were not told 
about DOACs. Wider literature indicated that high cost of 
a medicine is a barrier to its uptake.25 Specifically, studies 
with DOACs showed that prescribers in countries where 
patients were charged for medicines through insurance 
were less likely to prescribe DOACs, especially for 
patients with lower income.12–17,44 However, to our 
knowledge, no such studies in countries with national 
health services such as UK were reported. Further research 
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is needed to explore the impact of cost on the uptake of 
medicines deemed to be cost-effective in settings with 
national health service.
Consistent with prior survey research,30,45,46 patients 
experiencing joint or autonomous decision-making were 
told about more than one therapy option. They had an 
opportunity to voice their preferences, which were shaped 
by their knowledge about OAs gained from their clinicians 
or social network, perceived safety of OAs, and how well 
it would fit with their lifestyle and work arrangements. 
Familiarity with warfarin facilitated the choice of warfarin 
for some patients, whereas the unknown side and long- 
term effects, and lack of monitoring with DOACs raised 
safety concerns for others. Some patients who knew peo-
ple experiencing side effects with warfarin and the incon-
venience of taking it tended to choose DOAC therapy. 
These patients valued the lesser interference of the medi-
cine with their daily lives more than regular monitoring 
which was perceived to be a safety net by some patients. 
Also, knowledge about DOACs motivated some patients 
having challenges with warfarin therapy to enquire with 
clinicians about switching. Thus, lack of knowledge about 
DOACs and safety concerns acted as barriers to 
DOACs use.
Reported barriers for DOAC use led to some patients 
receiving warfarin therapy which did not align with their 
daily lives. Some patients reported it causing undue stress 
and non-adherence. Thus, addressing the identified barriers 
for DOACs use and patient involvement in decision-mak-
ing, could potentially achieve better therapy adherence, 
patient satisfaction with the consultation and therapy, and 
overall health.47
Implications for Practice
Our study findings outlined barriers to DOAC use and 
highlighted importance and challenges for patient involve-
ment in decision-making. In order to improve care for 
patients with AF, we recommend for health organizations 
and clinicians to consider:
● Developing and dedicating a team of healthcare pro-
fessionals with expertise in anticoagulation within 
GP practice to initiate OA therapy and provide con-
tinuity of ongoing care to build rapport with a 
patient.
● Lengthening consultation times (especially in pri-
mary care) when the decision to start an 
anticoagulation is being made to facilitate discussion 
of therapy options and address patients’ concerns.
● Providing periodic review of patients’ satisfaction 
with their current prescribed therapy and the option 
to consider alternative therapy options, which poten-
tially could identify and resolve difficulties patients 
experience that clinicians might not be aware of.
● Tailoring prescribed therapy to patients’ preferences 
to ensure the therapy fits with their daily lives.
Strengths and Limitations
The findings and transferability of findings to different 
settings and patient groups should be considered in the 
context of the study strengths and limitations. The main 
strength of this study was moderate sample size and 
recruitment of participants from three health economies 
with different anticoagulation service provision models. 
Also, semi-structured in-depth interviews provided rich 
and varied lived experiences, enabling greater insight 
into potential barriers for DOACs use. Lastly, data analysis 
robustness was ensured by more than one author being 
involved in the process and development of themes and 
subthemes.
We note the sample comprised almost exclusively of 
White British participants and more male patients were 
recruited, which is not fully representative of the wider 
population of the UK. However, AF is more prevalent in 
men.2 Clinical characteristics of patients (eg, comorbid-
ities) were not collected, which could have provided an 
extra dimension for interpretation of patients’ perspectives 
according to their personal stroke risk. The study also 
relied on participants’ accounts of consultations when 
OA therapy was initiated, which could be affected by 
recall bias. Lastly, participant validation, which could 
have increased internal validity of results, was not under-
taken. Instead, discussions with PPI advisory group were 
carried out to ensure data represented patients’ 
experiences.
Conclusion
This study has presented an in-depth evaluation of 
patients’ perspectives on potential barriers to DOAC use 
for stroke prevention in AF. Our findings suggested that 
perceived high DOAC cost, consultation time constraints, 
varying local services, lack of knowledge about DOACs, 
safety concerns about OAs, lack of patient involvement in 
decision-making, and prescribing habits favoring estab-
lished therapy were barriers to DOAC use. Lack of 
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consideration of OA therapy impact on daily lives and 
opportunity for patients to voice therapy preferences 
resulted in some patients being dissatisfied with the pre-
scribed therapy and management of difficulties caused by 
the prescribed medicine. Greater patient involvement in 
decision-making could prevent and resolve difficulties 
encountered by some patients and increase DOAC use.
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Supplementary file 1 Interview guide
Supplementary file 2 Description of health economies 
studied in the study.
Acknowledgments
The authors would like to thank the patients who gener-
ously gave their time to be interviewed, the Patient and 
Public Involvement advisory group for all their support 
throughout this study and the direct care team members 
who helped with the recruitment of participants. Also, we 
would like to thank the Pharmacy Research UK and Leeds 
Teaching Hospitals NHS Trust for the grant funding that 
enabled conduction of the study.
Funding
Financial support for this study was provided entirely by a 
grant from the Pharmacy Research UK (PRUK-2018-GA- 
1-KM) and Leeds Teaching Hospitals NHS Trust. The 
funding agreement ensured the authors’ independence in 
designing the study, interpreting the data, writing, and 
publishing the report. The views expressed are those of 
the author and not necessarily those of Pharmacy Research 
UK or Leeds Teaching Hospitals NHS Trust.
Disclosure
KM, SR, BF, MR, DP have no conflicts of interest to 
declare for this work. KS is employed by one of the 
sponsors of the study, reports grants from the Pharmacy 
Research UK and Leeds Teaching Hospitals NHS Trust 
during the conduct of the study, and reports no other 
potential conflicts of interest for this work.
References
1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiol-
ogy of atrial fibrillation: a Global Burden of Disease 2010 study. 
Circulation. 2014;129(8):837–847. doi:10.1161/CIRCULATION 
AHA.113.005119
2. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial 
fibrillation: an increasing epidemic and public health challenge. Int J 
Stroke. 2020;1–5. doi:10.1177/1747493019897870
3. Friberg L, Rosenqvist M, Lindgren A, et al. High prevalence of atrial 
fibrillation among patients with ischemic stroke. Stroke. 
2014;45:2599–2605. doi:10.1161/STROKEAHA.114.006070
4. The National Institute for Health Care and Excellence (NICE). Atrial 
fibrillation: management (CG180); 2020. Available from: https:// 
www.nice.org.uk/guidance/cg180. Accessed May 26, 2020.
5. Cowan JC, Wu J, Hall M, et al. A 10-year study of hospitalized atrial 
fibrillation-related stroke in England and its association with uptake 
of oral anticoagulants. Eur Heart J. 2018;39(32):2975–2983. 
doi:10.1093/eurheartj/ehy411
6. Kirchhof P, Benussi S, Kotecha D, et al. ESC guidelines for the 
management of atrial fibrillation developed in collaboration with 
EACTS. Eur Heart J. 2016;37:2893–2962.
7. The Task Force for the Management of Atrial Fibrillation of the 
European Society of Cardiology (ESC). Guidelines for the manage-
ment of atrial fibrillation. Eur Heart J. 2011;6:240–429.
8. The Task Force for the management of atrial fibrillation of the 
European Society of Cardiology (ESC). ESC guidelines for the 
management of atrial fibrillation developed in collaboration with 
EACTS. Eur Heart J. 2016;37:2893–2962.
9. Bai Y, Guo SD, Deng H, et al. Effectiveness and safety of oral 
anticoagulants in older patients with atrial fibrillation: a systematic 
review and meta-regression analysis. Age Ageing. 2018;47(1):9–17. 
doi:10.1093/ageing/afx103
10. Loo SY, Dell’Aniello S, Huiart L, et al. Trends in the prescription of 
novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 
2017;83(9):2096–2106. doi:10.1111/bcp.13299
11. ABPI SAFI. One year on: why patients still having unnecessary AF- 
related strokes? 2016. Available from: http://www.abpi.org.uk/media 
centre/newsreleases/2016/Documents/Embargo9May_ABPI_ 
OneYearOn_FINALREPORT.pdf. Accessed February 17, 2017.
12. AbuDagga A, Stephenson JJ, Fu AC, et al. Characteristics affecting 
oral anticoagulant therapy choice among patients with non-valvular 
atrial fibrillation: a retrospective claims analysis. BMC Health Serv 
Res. 2014;14:310. doi:10.1186/1472-6963-14-310
13. Baik SH, Hernandez I, Zhang Y. Evaluating the initiation of novel 
oral anticoagulants in medicare beneficiaries. J Manag Care Spec 
Pharm. 2016;22(3):281-292. doi:10.18553/jmcp.2016.22.3.281
14. Huang C, Siu M, Vu L, et al. Factors influencing doctors’ selection of 
dabigatran in non-valvular atrial fibrillation. J Eval Clin Pract. 
2013;19:938–943. doi:10.1111/j.1365-2753.2012.01886.x
15. Patel PA, Zhao X, Fonarow GC, et al. Novel oral anticoagulant use 
among patients with atrial fibrillation hospitalized with ischemic 
stroke or transient ischemic attack. Circ Cardiovasc Qual 
Outcomes. 2015;8(4):383–392. doi:10.1161/CIRCOUTCOM 
ES.114.000907
16. Potpara TS, Trendafilova E, Dan GA, et al. The patterns of Non- 
vitamin K Antagonist Oral Anticoagulants (NOACs) use in patients 
with atrial fibrillation in seven Balkan countries: a report from the 
BALKAN-AF survey. Adv Ther. 2017;34:2043–2057. doi:10.1007/ 
s12325-017-0589-5
17. Salmasi S, Kapanen AI, Kwan L, et al. Atrial fibrillation patients’ 
experiences and perspectives of anticoagulation therapy changes. Res 
Social Adm Pharm. 2020;16(10):1409–1415. doi:10.1016/j. 
sapharm.2020.01.004
18. Anderson TS, Lo-Ciganic WH, Gellad WF, et al. Patterns and pre-
dictors of physician adoption of new cardiovascular drugs. 
Healthcare. 2018;6:33–40. doi:10.1016/j.hjdsi.2017.09.004
19. Brais C, Larochelle J, Turgeon MH, et al. Predictors of direct oral 
anticoagulants utilization for thromboembolism prevention in atrial 
fibrillation. J Pharm Pharm. 2017;20:8–14.
20. Zhang Y, Méndez SJ, Scott A. Factors affecting general practitioners’ 
decisions to adopt new prescription drugs – cohort analyses using 
Australian longitudinal physician survey data. BMC Health Serv Res. 
2019;19(1):94. doi:10.1186/s12913-019-3889-4
Patient Preference and Adherence 2021:15                                                                                       https://doi.org/10.2147/PPA.S302016                                                                                                                                                                                                                       
DovePress                                                                                                                         
965
Dovepress                                                                                                                                                   Medlinskiene et al

































































21. Clarkesmith DE, Lip GHY, Lane DA. Patients’ experiences of atrial 
fibrillation and non-vitamin K antagonist oral anticoagulants 
(NOACs), and their educational needs: a qualitative study. Thromb 
Res. 2017;153:19–27. doi:10.1016/j.thromres.2017.03.002
22. Murphy A, Kirby A, Bradley C. Knowledge is power: general practi-
tioners prescribing of new oral anticoagulants in Ireland. BMC Res 
Notes. 2018;11:478–484. doi:10.1186/s13104-018-3597-x
23. Tanislav C, Allendorfer J, Pfeilschifter W, et al. One decade of oral 
anticoagulation in stroke patients: results from a large country-wide 
hospital-based registry. Int J Stroke. 2018;13(3):308–312. 
doi:10.1177/1747493017733928
24. Lo-Ciganic WH, Gellad WF, Huskamp HA, et al. Who were the early 
adopters of dabigatran? An application of group-based trajectory 
models. Med Care. 2016;54(7):725–732. doi:10.1097/ 
MLR.0000000000000549
25. Medlinskiene K, Tomlinson J, Marques I, et al. Barriers and 
Facilitators to Implementation of New Medicines into Clinical: A 
Systematic Review. Bradford: University of Bradford; 2020.
26. Department of Health. The NHS Constitution: the NHS belongs to us 
all; 2015. Available from: https://www.gov.uk/government/uploads/ 
system/uploads/attachment_data/file/480482/NNH_Constitution_ 
WEB.pdf. Accessed March 17, 2017.
27. Loughlin M, Buetow S, Cournoyea M, et al. Interactions between 
persons—knowledge, decision making, and the co-production of 
practice. J Eval Clin Pract. 2019;25:911–920. doi:10.1111/jep.13297
28. Borg CX, Shaw R, Lane DA. Patients’ and health professionals’ 
views and experiences of atrial fibrillation and oral-anticoagulation 
therapy: a qualitative meta-synthesis. Patient Educ Couns. 2012;88 
(2):330–337. doi:10.1016/j.pec.2012.05.011
29. Medlinskiene K, Petty D, Richardson S, et al. Are patients with non- 
valvular atrial fibrillation involved in decision-making about oral 
anticoagulants? A literature review. IJPP. 2018;26(1 Suppl):S42– 
S43.
30. Choi JC, DiBonaventura M, Kopenhafer L, et al. Survey of the use of 
warfarin and the newer anticoagulant dabigatran in patients with 
atrial fibrillation. Patient Prefer Adherence. 2014;8:167–177. 
doi:10.2147/PPA.S56187
31. Tomlinson J, Medlinskiene K, Cheong V, et al. Patient and public 
involvement in designing and conducting doctoral research: the whys 
and the hows. Res Involv Engagem. 2019;5(23). doi:10.1186/s40900- 
019-0155-1
32. Coyne IT. Sampling in qualitative research. Purposeful and theoreti-
cal sampling; merging or clear boundaries? J Adv Nurs. 1997;26 
(3):623–630. doi:10.1046/j.1365-2648.1997.t01-25-00999.x
33. Patton MQ. Qualitative Research and Evaluation Methods. London: 
SAGE publications; 2015.
34. Dantas GC, Thompson BV, Manson JA, et al. Patients’ perspectives 
on taking warfarin: qualitative study in family practice. BMC Fam 
Pract. 2004;5:15–24. doi:10.1186/1471-2296-5-15
35. Borg XC, Shaw RL, Lane DA. Patients’ and physicians’ experiences 
of atrial fibrillation consultations and anticoagulation decision-mak-
ing: a multi-perspective IPA design. Psychol Health. 2016;31(4):436– 
455. doi:10.1080/08870446.2015.1116534
36. Guest G, Bunce A, Johnson L. How many interviews are enough? An 
experiment with data saturation and variability. Field Methods. 
2006;18(1):59–82. doi:10.1177/1525822X05279903
37. Ritchie J, Lewis J, Nicholls C, et al. Qualitative Research Practice: A 
Guide for Social Science Students and Researchers. London: SAGE 
publications; 2014.
38. Gale NK, Heath G, Cameron E, et al. Using the framework method 
for the analysis of qualitative data in multi-disciplinary health 
research. BMC Medical Research Methodology. 2013;13(1):117– 
125. doi:10.1186/1471-2288-13-117
39. Parkinson S, Eatough V, Holmes J, et al. Framework analysis: a 
worked example of a study exploring young people’s experiences 
of depression. Qual Res Psychol. 2016;13(2):109–129. doi:10.1080/ 
14780887.2015.1119228
40. Nowell LS, Norris JM, White DE, et al. Thematic analysis: striving 
to meet the trustworthiness criteria. Int J Qual Methods. 2017;16 
(1):1–13. doi:10.1177/1609406917733847
41. Pritchett RV, Clarke JL, Jolly K, et al. Clinicians’ views and experi-
ences of prescribing oral anticoagulants for stroke prevention in atrial 
fibrillation: a qualitative meta-synthesis. PLoS One. 2020;15(5): 
e0232484. doi:10.1371/journal.pone.0232484
42. Beyene K, Chan AHY, Bandreddi NST, et al. Patient satisfaction with 
community pharmacist-led anticoagulation management services and 
its relationship with patient characteristics in New Zealand. Int J Clin 
Pharm. 2020. doi:10.1007/s11096-020-01124-y
43. Ingram SJ, Kirkdale CL, Williams S, et al. Moving anticoagulation 
initiation and monitoring services into the community: evaluation of 
the Brighton and Hove community pharmacy service. BMC Health 
Serv Res. 2018;18(1):91. doi:10.1186/s12913-018-2901-8
44. Kirley K, Goutham R, Bauer V, et al. The role of NOACs in atrial 
fibrillation management: a qualitative study. J Atr Fibrillation. 
2016;9(1):1416. doi:10.4022/jafib.1416
45. Andrade JG, Krahn AD, Skanes AC, et al. Value and preferences of 
physicians and patients with nonvalvular atrial fibrillation who 
receive oral anticoagulation therapy for stroke prevention. Can J 
Cardiol. 2017;32:747–753. doi:10.1016/j.cjca.2015.09.023
46. Baicus C, Balanescu P, Zeh S, et al. Characteristics of shared decision 
making in Romania from the patient perspective: a cross-sectional 
multicentric study. J Eval Clin. 2019;25:1152–1159. doi:10.1111/ 
jep.13257
47. Shay LA, Lafata JE. Where is the evidence? A systematic review of 
shared decision making and patient outcomes. Med Decis Making. 
2015;35(1):114–131. doi:10.1177/0272989X14551638
Patient Preference and Adherence                                                                                                    Dovepress 
Publish your work in this journal 
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal that focusing on the growing importance of 
patient preference and adherence throughout the therapeutic conti-
nuum. Patient satisfaction, acceptability, quality of life, compliance, 
persistence and their role in developing new therapeutic modalities 
and compounds to optimize clinical outcomes for existing disease 
states are major areas of interest for the journal. This journal has 
been accepted for indexing on PubMed Central. The manuscript 
management system is completely online and includes a very quick 
and fair peer-review system, which is all easy to use. Visit http:// 
www.dovepress.com/testimonials.php to read real quotes from pub-
lished authors.  
Submit your manuscript here: https://www.dovepress.com/patient-preference-and-adherence-journal
DovePress                                                                                                             Patient Preference and Adherence 2021:15 966
Medlinskiene et al                                                                                                                                                   Dovepress
Powered by TCPDF (www.tcpdf.org)
P
at
ie
nt
 P
re
fe
re
nc
e 
an
d 
A
dh
er
en
ce
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
86
.7
.9
0.
21
2 
on
 2
2-
Ju
l-2
02
1
F
or
 p
er
so
na
l u
se
 o
nl
y.
